Insperity has surged 28% in a month to $53.18, and now it faces a second earnings print in three days — this one on July 31 — with the bear trade already in retreat but the analyst community still not buying the recovery.
The short-covering story that defined the post-July 29 session is continuing. Short interest has fallen 11.6% on the week to 10.0% of the free float, down from the 11.3% level flagged before the previous print. That covering is orderly, not panicked: cost to borrow remains negligible at 0.51%, and availability is running at 484% — more than four shares available to lend for every one already borrowed. Shorts who remain are holding at minimal cost with no squeeze pressure forcing their hand. Options have also pulled back from last week's extreme. The put/call ratio now reads 2.37, still well above its 20-day average of 1.89, but down sharply from the 2.72 peak that flagged maximum defensiveness ahead of the July 29 report. The hedging impulse has eased — it hasn't disappeared.
The analyst debate is the sharpest tension heading into Thursday. Truist Securities lifted its target from $35 to $52 on July 22, one of the more notable upward revisions in recent months, yet kept its rating at Hold. With the stock now trading just above that revised target at $53.18, the Street's consensus mean of $45 sits below the current price — meaning the average analyst thinks the recent rally has gone too far. JP Morgan, which has maintained an Underweight since at least early 2025, last set its target at $33. Bulls point to projected 4% revenue growth, the Workday partnership's potential to deepen client retention in the mid-market, and a PEO sector that structurally benefits from small-business demand for outsourced HR. Bears counter that weaker hiring activity among workforce service employees, persistent healthcare cost pressure, and a disappointing Q2 that missed estimates tell a harder story about the underlying business.
The CEO's own money is squarely in the bull camp. Paul Sarvadi bought roughly $15.7 million in net shares between mid-March and early June — across multiple tranches, at prices ranging from $22 to $34 — and his stake now represents 4.6% of shares outstanding. That buying cluster started well below current levels and has proven timely. Among institutional holders, Invesco added over 1.25 million shares as of Q1, and SEI Investments added 423,000 shares as of June 30. The ownership picture broadly reflects accumulation during the downturn, not distribution at the highs.
What Thursday's print tests is whether the operational recovery is real and durable — specifically, whether healthcare cost headwinds have peaked, whether WSEE growth is returning to positive territory, and whether management can offer guidance that justifies a stock price that has now lapped most of its analyst targets.
See the live data behind this article on ORTEX.
Open NSP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
